公开(公告)号：US20190247303A1

公开(公告)日：2019-08-15

申请号：US16346051

申请日：2017-10-31

Applicant: VECTURA LIMITED ,  UCB BIOPHARMA SPRL

Inventor： Frazer Giles MORGAN ,  Mark Jonathan MAIN ,  Roger PALFRAMAN ,  David KIRKE

IPC: A61K9/00 ,  A61K9/16 ,  C07K16/24 ,  A61P11/06

CPC classification number: A61K9/0075 ,  A61K9/1617 ,  A61K9/1623 ,  A61K2039/505 ,  A61K2039/544 ,  A61K2039/545 ,  A61P11/06 ,  C07K16/244 ,  C07K2317/24 ,  C07K2317/76 ,  C07K2317/90

Abstract: An inhalable powder composition comprises a) an antagonistic antibody which binds human IL-13, b) leucine and c) trehalose. The antibody may comprise a heavy chain, wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:3 and a light chain, wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:1. Also described is the use of such compositions in the treatment of asthma, as well as inhalers containing such compositions.

公开(公告)号：US10358493B2

公开(公告)日：2019-07-23

申请号：US15311198

申请日：2015-05-28

Applicant: UCB BIOPHARMA SPRL

Inventor： Helene Margaret Finney ,  Stephen Edward Rapecki ,  Michael John Wright

IPC: C07K16/00 ,  C07K16/28 ,  C07K16/14 ,  C07K16/46 ,  G01N33/68

Abstract: The present disclosure relates to a novel bispecific protein complex and a method of using the complexes to screen for synergistic or novel biological function. The bispecific format is particularly suitable for high-throughput screening because all of its components can be expressed from cells as individual units and the units can be assembled simply by mixing without employing conjugation or coupling chemistry.

公开(公告)号：US10316097B2

公开(公告)日：2019-06-11

申请号：US15577035

申请日：2016-05-25

Applicant: UCB BIOPHARMA SPRL

Inventor： Patrice Marie Charles Godard ,  Rafal Marian Kaminski ,  Karine Josee Jeanne Leclercq ,  Jonathan Marie M Van Eyll

IPC: G01N33/53 ,  A61K39/395 ,  C07K14/475 ,  C07K14/48 ,  A61K38/00 ,  A61K38/18 ,  A61K49/00 ,  A61K49/16 ,  A61K38/19 ,  A61K38/20 ,  A61K38/21 ,  A61K38/17 ,  C07K14/47 ,  C07K16/28 ,  A61P25/28 ,  A61P25/18 ,  A61P25/16 ,  A61K39/00

Abstract: The present invention pertain an inhibitor of CSF-1R activity for use in the treatment and/or prophylaxis of neurologic diseases and new method of treatment of neurologic diseases.

公开(公告)号：US10308723B2

公开(公告)日：2019-06-04

申请号：US15482260

申请日：2017-04-07

Applicant: UCB BIOPHARMA SPRL

Inventor： Ralph Adams ,  Andrew George Popplewell ,  Stephen Edward Rapecki

IPC: A61K39/395 ,  C07K16/46 ,  C07K16/24

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

公开(公告)号：US20190144565A1

公开(公告)日：2019-05-16

申请号：US16307454

申请日：2017-06-08

Applicant: UCB BIOPHARMA SPRL

Inventor： Ralph ADAMS ,  Thomas Allen CESKA ,  Anna Marie DAVIES ,  Alistair James HENRY ,  Xiaofeng LIU ,  James Michael MCDONNELL ,  Brian John SUTTON ,  Marta Katarzyna WESTWOOD

IPC: C07K16/42 ,  C07K16/28 ,  A61P37/08

Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the FcεRI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the Cε2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the Cε2 domain of IgE) and/or the ability to disassociate IgE from the FcεRI receptor for instance at pharmaceutically-relevant concentrations. In one aspect, improved or novel treatments for IgE mediated disorders are disclosed in which IgE is targeted (for instance free IgE and/or IgE complexed with the FcεRI receptor).

公开(公告)号：US20190106406A1

公开(公告)日：2019-04-11

申请号：US16086698

申请日：2017-04-07

Applicant: UCB Biopharma SPRL

Inventor： Ali Ates ,  Eric Jnoff ,  Laurent Provins ,  Anne Valade ,  Adrian Hall

IPC: C07D401/06 ,  C07D471/04

CPC classification number: C07D401/06 ,  C07D217/06 ,  C07D403/06 ,  C07D471/04

Abstract: The present invention relates to tetrahydroisoquinoline derivatives according to formula (I), wherein G represents a fused heterocyclic system selected from the groups represented by formula (G1), (G2), (G3), (G4), (G5), and (G6), which are Positive Allosteric Modulators of D1 and accordingly of benefit as pharmaceutical agents for the treatment of diseases in which D1 receptors play a role.

公开(公告)号：US20180346604A1

公开(公告)日：2018-12-06

申请号：US15779426

申请日：2016-12-01

Applicant: UCB BIOPHARMA SPRL

Inventor： Stephen Edward RAPECKI

IPC: C07K16/46 ,  C07K14/39 ,  C07K16/14 ,  G01N33/68

CPC classification number: C07K16/468 ,  C07K14/39 ,  C07K16/00 ,  C07K16/14 ,  C07K2319/00 ,  G01N33/6854

Abstract: The present invention relates to a method of identifying, separating and characterizing a cell or a population of cells, by capturing at the cell surface, secreted soluble substances (such as an immunoglobulin) that cell or population of cell secrete. This is achieved by combing on a heterodimerically-tethered multispecific protein complex combining a binding specificity for the secreted molecule and a binding specificity for a surface antigen specific for that cell or population of cells. This method may be used in research and experimental purposes, such as patients' stratification in preparation of clinical trials or personalized therapies by identifying cell populations relevant to a pathology and/or prognosis.

公开(公告)号：US10093652B2

公开(公告)日：2018-10-09

申请号：US15038287

申请日：2014-12-08

Applicant: UCB Biopharma SPRL

Inventor： Jag Paul Heer ,  Victoria Elizabeth Jackson ,  Boris Kroeplien ,  Fabien Claude Lecomte ,  John Robert Porter

IPC: A61K35/28 ,  A01N1/02 ,  G01N33/569 ,  C12N5/0789 ,  C07D401/10 ,  C07D235/12 ,  A61K31/4439

Abstract: A series of substituted 4,5,6,7-tetrahydrobenzimidazole derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

公开(公告)号：US20180273620A1

公开(公告)日：2018-09-27

申请号：US15743756

申请日：2016-07-15

Applicant: UCB Biopharma SPRL

Inventor： Helene Margaret FINNEY ,  Stephen Edward RAPECKI ,  Kerry Louise TYSON ,  Michael John WRIGHT

IPC: C07K16/28

Abstract: The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.

公开(公告)号：US20180222868A1

公开(公告)日：2018-08-09

申请号：US15580054

申请日：2016-06-07

Applicant: UCB Biopharma SPRL

Inventor： Prafulkumar Tulshibhai Chovatia ,  Martin Clive Hutchings ,  Boris Kroeplien ,  James Thomas Reuberson

IPC: C07D231/56 ,  A61K31/416 ,  C07D403/04 ,  A61K31/506 ,  C07D403/14 ,  C07D413/14

CPC classification number: C07D231/56 ,  A61K31/416 ,  A61K31/506 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14

Abstract: A series of substituted indazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.